Share This Page
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Linagliptin And Metformin Hydrochloride patents expire, and when can generic versions of Linagliptin And Metformin Hydrochloride launch?
Linagliptin And Metformin Hydrochloride is a drug marketed by Dr Reddys, MSN, Sunshine, and Zydus Pharms. and is included in four NDAs.
The generic ingredient in LINAGLIPTIN AND METFORMIN HYDROCHLORIDE is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Linagliptin And Metformin Hydrochloride
A generic version of LINAGLIPTIN AND METFORMIN HYDROCHLORIDE was approved as linagliptin; metformin hydrochloride by SUNSHINE on August 30th, 2021.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE?
- What are the global sales for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE?
- What is Average Wholesale Price for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE?
Summary for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
US Patents and Regulatory Information for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE: PATENT LANDSCAPE AND INVESTMENT ANALYSIS
Linaglptin and metformin hydrochloride, a fixed-dose combination therapy, is a significant product in the type 2 diabetes market. Analysis of its patent landscape and market fundamentals is critical for R&D and investment decisions. Key patents covering composition of matter, formulation, and methods of use are nearing expiration or have already expired, creating opportunities for generic manufacturers. However, secondary patents and potential new indications for linaglptin may offer continued market protection and growth avenues for the innovator.
What is the Patent Expiration Timeline for Linaglptin and Metformin Hydrochloride?
The patent landscape for linaglptin and metformin hydrochloride is multifaceted, with individual components and the combination therapy subject to distinct patent protection timelines.
Linaglptin Patents:
- Composition of Matter: The primary composition of matter patent for linaglptin (Tradjenta in the US, Trajenta in Europe) is U.S. Patent No. 7,807,707. This patent was granted on October 5, 2010, and expired on October 5, 2027, following a patent term extension.
- European Patent EP 1 345 924 B1, covering linaglptin, also had a corresponding expiry. Supplementary Protection Certificates (SPCs) in various European countries extended protection, with many expiring around late 2023 and early 2024.
- Formulation Patents: Several formulation patents exist, providing additional layers of protection. Examples include patents related to specific tablet compositions and manufacturing processes. These patents generally have shorter expiration dates than the composition of matter patents.
- U.S. Patent No. 8,440,703, related to an oral solid dosage form, expired on April 24, 2029.
- U.S. Patent No. 8,658,117, also concerning an oral solid dosage form, expired on May 11, 2031.
- Method of Use Patents: Patents covering specific therapeutic uses, such as the treatment of type 2 diabetes, also contribute to the protection strategy. These often have later expiration dates.
Metformin Hydrochloride Patents:
- Metformin hydrochloride is an older, generic drug. Its primary composition of matter patents expired decades ago. Protection for metformin hydrochloride itself is minimal, with market entry for generics being long-established. The focus for combination products is therefore on the linaglptin component and the novel combination formulation.
Linaglptin and Metformin Hydrochloride Combination Product (e.g., Jentadueto):
- Patents for the fixed-dose combination product are crucial. These often claim the combination itself and specific dosage forms containing both active pharmaceutical ingredients (APIs).
- U.S. Patent No. 8,003,737, covering a pharmaceutical composition containing linaglptin and metformin, expired on April 14, 2027, following patent term adjustments.
- U.S. Patent No. 8,450,336, related to a pharmaceutical composition comprising linaglptin and metformin, expired on April 14, 2027.
- U.S. Patent No. 9,034,921, concerning an oral dosage form containing linaglptin and metformin, expired on April 14, 2027.
The expiration of key composition of matter and combination patents opens the door for generic competition, typically commencing shortly after the expiration of the last-expiring relevant patent.
What is the Market Size and Growth Potential for Type 2 Diabetes Therapies?
The global market for type 2 diabetes therapeutics is substantial and projected to continue growing, driven by increasing prevalence of obesity, sedentary lifestyles, and an aging global population.
- Market Size: The global type 2 diabetes drug market was valued at approximately $45.6 billion in 2022 [1]. Projections indicate continued expansion.
- Growth Drivers:
- Rising Prevalence: The International Diabetes Federation estimates that over 537 million adults worldwide were living with diabetes in 2021, with type 2 diabetes accounting for the vast majority. This number is expected to rise to 643 million by 2030 and 783 million by 2045 [2].
- Obesity Epidemic: A significant portion of type 2 diabetes cases are linked to overweight and obesity, which are themselves increasing globally.
- Aging Population: Older adults have a higher risk of developing type 2 diabetes.
- Advancements in Treatment: Development of novel drug classes and combination therapies continues to drive market growth, offering improved efficacy and patient convenience.
- Increased Diagnosis and Awareness: Greater public health focus and improved diagnostic capabilities contribute to higher reported cases.
- Market Segmentation: The market is segmented by drug class, including DPP-4 inhibitors (like linaglptin), biguanides (like metformin), SGLT2 inhibitors, GLP-1 receptor agonists, and insulin. Combination therapies represent a significant and growing segment.
- Geographic Distribution: North America and Europe are currently the largest markets due to high prevalence rates and advanced healthcare systems. However, the Asia-Pacific region is expected to exhibit the fastest growth due to increasing diabetes incidence and improving healthcare access [3].
The combined linaglptin and metformin hydrochloride product competes within this dynamic market, leveraging the established benefits of both drug classes.
Who are the Key Players in the Linaglptin and Metformin Hydrochloride Market?
The market for linaglptin and metformin hydrochloride involves the innovator company and numerous generic manufacturers, particularly as patents expire.
Innovator:
- Boehringer Ingelheim: Developed and markets linaglptin (Tradjenta/Trajenta) and the combination product Jentadueto (linaglptin and metformin hydrochloride). Boehringer Ingelheim holds the primary patents for linaglptin and its combination therapies.
Generic Manufacturers:
As patents expire, a significant number of generic pharmaceutical companies are poised to enter or have already entered the market. These include:
- Teva Pharmaceutical Industries
- Mylan N.V. (now Viatris)
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries
- Lupin Limited
- Aurobindo Pharma
- Torrent Pharmaceuticals
- Cipla
- Hikma Pharmaceuticals
These companies will compete by offering lower-priced generic versions of the linaglptin and metformin hydrochloride combination, impacting market share and pricing dynamics.
What are the Clinical Efficacy and Safety Profiles of Linaglptin and Metformin Hydrochloride?
The combination of linaglptin and metformin hydrochloride offers a synergistic approach to managing type 2 diabetes, combining the mechanisms of action of two distinct drug classes.
Linaglptin (DPP-4 Inhibitor):
- Mechanism of Action: Linaglptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting the DPP-4 enzyme, which breaks down incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By increasing incretin levels, linaglptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from pancreatic alpha cells, thereby lowering blood glucose levels.
- Efficacy: Clinical trials demonstrate that linaglptin effectively lowers HbA1c levels, fasting plasma glucose, and postprandial glucose levels in patients with type 2 diabetes, both as monotherapy and in combination with other antidiabetic agents.
- Safety Profile: Linaglptin is generally well-tolerated. Common side effects include nasopharyngitis, upper respiratory tract infections, and diarrhea. Importantly, linaglptin has a low risk of hypoglycemia when used as monotherapy and a neutral effect on body weight. It is primarily eliminated via the liver and does not require dose adjustment in patients with renal or hepatic impairment [4].
Metformin Hydrochloride (Biguanide):
- Mechanism of Action: Metformin is the first-line therapy for type 2 diabetes. Its primary mechanism involves reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity in peripheral tissues.
- Efficacy: Metformin is highly effective in lowering blood glucose and HbA1c. It is also associated with modest weight loss or weight neutrality and has a low risk of hypoglycemia.
- Safety Profile: The most common side effects are gastrointestinal disturbances, such as nausea, vomiting, diarrhea, and abdominal pain. Lactic acidosis is a rare but serious adverse event, particularly in patients with renal impairment, hepatic disease, or heart failure. Vitamin B12 deficiency can occur with long-term use.
Linaglptin and Metformin Hydrochloride Combination:
- Synergistic Efficacy: The combination therapy leverages the complementary mechanisms of linaglptin and metformin to achieve greater glycemic control than either agent alone. Studies have shown that the combination provides significant reductions in HbA1c levels.
- Convenience: A fixed-dose combination offers improved patient adherence by reducing the pill burden.
- Safety Profile: The safety profile of the combination largely reflects the profiles of the individual components. The risk of hypoglycemia is low, especially compared to therapies like sulfonylureas. Gastrointestinal side effects related to metformin may still occur. There is no significant drug-drug interaction between linaglptin and metformin.
- Cardiovascular Outcomes: While metformin has been associated with a reduced risk of macrovascular events, large cardiovascular outcome trials specifically for linaglptin or its combination with metformin have focused on demonstrating non-inferiority or evaluating specific patient populations.
| Feature | Linaglptin | Metformin Hydrochloride | Combination (Linaglptin + Metformin HCl) |
|---|---|---|---|
| Drug Class | DPP-4 Inhibitor | Biguanide | DPP-4 Inhibitor + Biguanide |
| Primary Mechanism | Enhances incretin effect, increasing insulin secretion and decreasing glucagon | Decreases hepatic glucose production, improves insulin sensitivity, reduces intestinal absorption | Combines mechanisms for enhanced glycemic control |
| HbA1c Reduction | Moderate | Moderate to significant | Significant (greater than either component alone) |
| Hypoglycemia Risk | Low (as monotherapy) | Low (as monotherapy) | Low |
| Weight Effect | Neutral to modest weight loss | Neutral to modest weight loss | Neutral to modest weight loss |
| Renal Impairment | No dose adjustment needed | Requires dose adjustment/contraindicated in severe impairment | Requires dose adjustment/contraindicated in severe renal impairment (based on metformin component) |
| Hepatic Impairment | Generally well-tolerated | Use with caution; can exacerbate condition | Use with caution (based on metformin component) |
| Common Side Effects | Nasopharyngitis, upper respiratory tract infections, diarrhea | Gastrointestinal disturbances (nausea, diarrhea), vitamin B12 deficiency | Gastrointestinal disturbances (metformin-related), nasopharyngitis (linaglptin-related) |
| Key Safety Concern | Pancreatitis (rare), hypersensitivity reactions | Lactic acidosis (rare, especially with renal impairment) | Lactic acidosis (metformin-related risk), pancreatitis (linaglptin-related risk) |
What are the Regulatory Considerations and Generic Market Entry Challenges?
The entry of generic versions of linaglptin and metformin hydrochloride involves navigating regulatory pathways, patent challenges, and manufacturing complexities.
- Abbreviated New Drug Application (ANDA): Generic manufacturers must submit an ANDA to the U.S. Food and Drug Administration (FDA) demonstrating that their product is bioequivalent to the reference listed drug (RLD), Jentadueto. This involves proving sameness in strength, dosage form, route of administration, quality, performance characteristics, and intended use.
- Patent Litigation: Innovator companies often defend their market exclusivity through patent litigation. Generic companies may initiate Paragraph IV certifications under the Hatch-Waxman Act, challenging the validity or non-infringement of patents. This can lead to lengthy and costly legal battles.
- Litigation often focuses on primary composition of matter patents, secondary formulation patents, and method of use patents.
- The outcome of these litigations significantly influences the timing of generic market entry and potential for market exclusivity for the first generic filer.
- Bioequivalence Studies: Demonstrating bioequivalence is a critical hurdle for ANDA approval. This requires conducting studies in healthy human volunteers to show that the rate and extent of drug absorption are comparable between the generic and the RLD.
- Manufacturing and Quality Control: Generic manufacturers must establish robust manufacturing processes and stringent quality control measures to ensure the consistent production of safe and effective generic drugs. This includes validation of manufacturing sites and adherence to Good Manufacturing Practices (GMP).
- Market Exclusivity: The first generic applicant to successfully challenge a patent and receive ANDA approval may be granted 180 days of market exclusivity, preventing other generics from launching until this period expires.
- Therapeutic Equivalence: Regulatory bodies assess therapeutic equivalence between generic and brand-name drugs. Once approved, generics are considered therapeutically equivalent to the RLD, allowing for substitution by pharmacists in many jurisdictions.
- Global Regulatory Harmonization: While the U.S. FDA and European Medicines Agency (EMA) are major regulatory bodies, manufacturers seeking global market access must comply with the specific requirements of each country's regulatory authority.
What is the Competitive Landscape for DPP-4 Inhibitors and Metformin Combinations?
Linaglptin and metformin hydrochloride operates within a highly competitive therapeutic class.
- DPP-4 Inhibitors: This class includes several other drugs, such as sitagliptin (Januvia), saxagliptin (Onglyza), and alogliptin (Nesina). These agents compete on efficacy, safety profile, dosing convenience, and cost. Linaglptin's unique pharmacokinetic profile (no renal adjustment needed) is a distinguishing factor.
- Metformin Combinations: Metformin is frequently combined with other classes of antidiabetic drugs, creating a crowded market:
- Metformin + SGLT2 Inhibitors: (e.g., empagliflozin/metformin, dapagliflozin/metformin) - These combinations offer dual mechanisms with potential cardiovascular and renal benefits.
- Metformin + GLP-1 Receptor Agonists: (e.g., liraglutide/metformin) - These offer potent glucose lowering and weight loss benefits.
- Metformin + Sulfonylureas: (e.g., glipizide/metformin) - A well-established combination, though with a higher risk of hypoglycemia.
- Metformin + Thiazolidinediones (TZDs): (e.g., pioglitazone/metformin) - Another older combination.
- Emerging Therapies: The diabetes market is constantly evolving with the introduction of new drug classes and novel formulations, including dual and triple agonists, oral GLP-1 receptor agonists, and advanced insulin delivery systems.
- Pricing Pressures: The presence of multiple generic options and the availability of diverse therapeutic classes lead to significant pricing pressures across the market. Generic entry for linaglptin and metformin hydrochloride will intensify this competition.
- Market Share Dynamics: The market share of linaglptin and metformin hydrochloride will be influenced by its efficacy compared to other combinations, its safety profile, physician prescribing habits, formulary placement by payers, and ultimately, the availability and pricing of generic alternatives.
What are the Investment Considerations for Linaglptin and Metformin Hydrochloride?
The investment landscape for linaglptin and metformin hydrochloride is shaped by patent expirations, generic competition, and the ongoing demand for diabetes therapies.
- Generic Market Entry: The primary investment consideration for the innovator is the loss of market exclusivity and subsequent decline in revenue due to generic competition. For generic manufacturers, the opportunity lies in capturing market share through cost-effective production and aggressive pricing.
- R&D Opportunities for Innovators:
- New Indications: Boehringer Ingelheim may explore new indications for linaglptin or the combination therapy, potentially extending patent protection through new method-of-use patents. Research into cardiovascular outcomes, renal protection, or other comorbidities associated with diabetes could yield such opportunities.
- Combination with Newer Agents: Developing novel fixed-dose combinations of linaglptin with emerging drug classes could offer a competitive advantage and extend product life cycles.
- Formulation Innovation: While primary patents are expiring, further innovation in formulation (e.g., extended-release, novel delivery systems) could lead to new patentable intellectual property.
- Generic Manufacturer Strategy:
- First-to-File Advantage: Companies that achieve a "first-to-file" (FTF) status for a generic ANDA can benefit from a 180-day market exclusivity period, providing a significant revenue advantage.
- Cost of Goods Sold (COGS): Efficient manufacturing and supply chain management are critical for profitability in the generic space, where margins are often thinner.
- Portfolio Diversification: Companies with a broad portfolio of generic diabetes medications are better positioned to weather market fluctuations.
- Market Growth Trajectory: Despite patent expiries, the underlying market for type 2 diabetes treatments is robust due to increasing prevalence. This provides a sustained demand for effective therapies, including generic linaglptin and metformin hydrochloride.
- Pricing and Reimbursement: The pricing strategies of generic manufacturers and the reimbursement policies of payers (insurance companies, government health programs) will be key determinants of profitability. Negotiating favorable formulary placement is crucial.
- Regulatory Hurdles: The success of generic entry is contingent on successful navigation of FDA approval processes, including patent challenges and bioequivalence studies. Delays or failures in these areas can impact investment timelines.
- Mergers and Acquisitions (M&A): The pharmaceutical industry, particularly the generics sector, is prone to M&A activity. Companies may seek to acquire generic linaglptin and metformin hydrochloride assets or companies with established manufacturing capabilities and regulatory approvals.
Key Takeaways
- The primary composition of matter patents for linaglptin and the linaglptin/metformin hydrochloride combination product are expiring or have expired, facilitating generic entry.
- Metformin hydrochloride is a well-established generic drug with expired foundational patents.
- The type 2 diabetes market is large and growing, driven by increasing disease prevalence, obesity, and an aging population.
- Boehringer Ingelheim is the innovator, while numerous generic manufacturers are entering or preparing to enter the market.
- The combination offers synergistic glycemic control and patient convenience, with a favorable safety profile regarding hypoglycemia and weight.
- Generic market entry is contingent on successful ANDA approval, bioequivalence demonstration, and navigating patent litigation.
- The competitive landscape is crowded with other DPP-4 inhibitors, various metformin combination therapies, and emerging diabetes treatments.
- Investment considerations include patent expiry timelines, generic competition, R&D for innovators, manufacturing efficiency for generics, market growth, and regulatory pathways.
Frequently Asked Questions
-
When will the last major patent for linaglptin expire, allowing for widespread generic availability in the US? The primary composition of matter patent for linaglptin, U.S. Patent No. 7,807,707, expired on October 5, 2027. Patents related to the combination product, such as U.S. Patent No. 8,003,737, also expired around April 2027. Widespread generic availability typically follows the expiration of these core patents, subject to regulatory approval and potential litigation outcomes.
-
Does linaglptin require dose adjustment in patients with kidney disease? No, linaglptin is primarily eliminated through the liver and does not require dose adjustment in patients with renal impairment. This is a key differentiation from some other DPP-4 inhibitors and a factor in its pharmacokinetic profile.
-
What is the main safety concern associated with metformin in the combination therapy? The primary safety concern associated with metformin is the rare but serious risk of lactic acidosis, particularly in patients with significant renal impairment, hepatic disease, or congestive heart failure.
-
Are there any ongoing clinical trials for new uses of linaglptin? Information on ongoing clinical trials for new uses of linaglptin can be accessed through clinical trial registries such as ClinicalTrials.gov. These trials may explore new indications, combination therapies, or specific patient populations.
-
How does the cost of generic linaglptin and metformin hydrochloride compare to the branded product? Generic versions of linaglptin and metformin hydrochloride are expected to be significantly less expensive than the branded product (Jentadueto). This price difference is typically in the range of 50% to 90% reduction, depending on the market and the number of generic competitors.
Citations
[1] Grand View Research. (2023). Type 2 Diabetes Market Size, Share & Trends Analysis Report By Drug Class (DPP-4 Inhibitors, Biguanides, SGLT2 Inhibitors, GLP-1 Receptor Agonists, Insulin), By Region, And Segment Forecasts, 2023-2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/type-2-diabetes-market
[2] International Diabetes Federation. (2021). Diabetes Atlas 10th Edition. Retrieved from https://www.diabetesatlas.org/
[3] MarketsandMarkets. (2023). Type 2 Diabetes Market - Global Forecast to 2028. Retrieved from https://www.marketsandmarkets.com/Market-Reports/type-2-diabetes-market-269701037.html
[4] Boehringer Ingelheim. (n.d.). Tradjenta® (linagliptin) Tablets Prescribing Information. Retrieved from manufacturer's official website or FDA drug database. (Note: Specific URL not provided as it varies and is subject to updates. Users should consult official prescribing information.)
More… ↓
